Kowa Company, Ltd. - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kowa Company, Ltd. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Kowa Company, Ltd. - Product Pipeline Review - 2016', provides an overview of the Kowa Company, Ltd.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Kowa Company, Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kowa Company, Ltd.
- The report provides overview of Kowa Company, Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Kowa Company, Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Kowa Company, Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Kowa Company, Ltd.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kowa Company, Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kowa Company, Ltd.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Kowa Company, Ltd. Snapshot 6
Kowa Company, Ltd. Overview 6
Key Information 6
Key Facts 6
Kowa Company, Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Kowa Company, Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Kowa Company, Ltd. - Pipeline Products Glance 14
Kowa Company, Ltd. - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Kowa Company, Ltd. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Kowa Company, Ltd. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Kowa Company, Ltd. - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Kowa Company, Ltd. - Drug Profiles 21
pemafibrate 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
anagliptin 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
peretinoin 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
K-134 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ripasudil 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
epirubicin hydrochloride 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
K-312 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
pitavastatin NP 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule to Agonize LXRB for Atherosclerosis 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
K-163SZ 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Kowa Company, Ltd. - Pipeline Analysis 38
Kowa Company, Ltd. - Pipeline Products by Target 38
Kowa Company, Ltd. - Pipeline Products by Route of Administration 40
Kowa Company, Ltd. - Pipeline Products by Molecule Type 41
Kowa Company, Ltd. - Pipeline Products by Mechanism of Action 42
Kowa Company, Ltd. - Recent Pipeline Updates 44
Kowa Company, Ltd. - Dormant Projects 47
Kowa Company, Ltd. - Discontinued Pipeline Products 48
Discontinued Pipeline Product Profiles 48
pitavastatin CR 48
Kowa Company, Ltd. - Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Kowa Company, Ltd., Key Information 6
Kowa Company, Ltd., Key Facts 6
Kowa Company, Ltd. - Pipeline by Indication, 2016 9
Kowa Company, Ltd. - Pipeline by Stage of Development, 2016 10
Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2016 11
Kowa Company, Ltd. - Partnered Products in Pipeline, 2016 12
Kowa Company, Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 13
Kowa Company, Ltd. - Pre-Registration, 2016 14
Kowa Company, Ltd. - Phase III, 2016 15
Kowa Company, Ltd. - Phase II, 2016 16
Kowa Company, Ltd. - Phase I, 2016 17
Kowa Company, Ltd. - Preclinical, 2016 18
Kowa Company, Ltd. - Discovery, 2016 19
Kowa Company, Ltd. - Unknown, 2016 20
Kowa Company, Ltd. - Pipeline by Target, 2016 39
Kowa Company, Ltd. - Pipeline by Route of Administration, 2016 40
Kowa Company, Ltd. - Pipeline by Molecule Type, 2016 41
Kowa Company, Ltd. - Pipeline Products by Mechanism of Action, 2016 43
Kowa Company, Ltd. - Recent Pipeline Updates, 2016 44
Kowa Company, Ltd. - Dormant Developmental Projects,2016 47
Kowa Company, Ltd. - Discontinued Pipeline Products, 2016 48
Kowa Company, Ltd., Other Locations 49
Kowa Company, Ltd., Subsidiaries 50